2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  The Lancet

• Publication date

  2007-01-06

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0140-6736(07)60028-2PMID 17208639
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.

  2006cited by this paper
• The ne w e ngl and j our na l of medicine

  2006cited by this paper
• Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience.

  2006cited by this paper
• Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

  2005cited by this paper
• Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

  2005cited by this paper
• Trastuzumab in the treatment of breast cancer.

  2005cited by this paper
• Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.

  2005cited by this paper
• Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

  2005cited by this paper
• Herceptin and early breast cancer: a moment for caution.

  2005cited by this paper
• A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.

  2005cited by this paper
• Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

  2005cited by this paper
• Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule.

  2005cited by this paper
• The discovery of receptor tyrosine kinases: targets for cancer therapy

  2004cited by this paper
• Switching to exemestane after 2-3 years of adjuvant tamoxifen prolongs disease-free survival, but not overall survival, in postmenopausal women surviving primary breast cancer, compared with continuous tamoxifen.

  2004cited by this paper
• A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer*

  2004cited by this paper
• Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.

  2002cited by this paper
• Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.

  2002cited by this paper
• Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

  2001cited by this paper
• Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anti-cancer activity: a randomised multinational controlled phase III trial

  1998cited by this paper
• Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

  1989cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper
• Improved survival among patients treated with adjuvant tamoxifen after mastectomy for early breast cancer.

  1983cited by this paper
• IMPROVED SURVIVAL AMONGST PATIENTS TREATED WITH ADJUVANT TAMOXIFEN AFTER MASTECTOMY FOR EARLY BREAST CANCER

  1983cited by this paper
• Combination chemotherapy as an adjuvant treatment in operable breast cancer.

  1976cited by this paper

• Preferential HER4 stimulation preserves neuregulin-induced improvement of myocardial function

  2026cites this paper
• Review of the clinical status of cardiotoxicity of HER-2 positive breast cancer targeted therapeutic drugs

  2025cites this paper
• Triple-positive breast cancer: navigating heterogeneity and advancing multimodal therapies for improving patient outcomes

  2025cites this paper
• Comparison of pathological complete response (pCR) between short-term (<6 cycles) and long-term (≥6 cycles) neoadjuvant trastuzumab therapy for HER2-positive breast cancer: a systematic review and meta-analysis of randomized controlled trials

  2025cites this paper
• Cardio-Oncology and Breast Cancer Therapies

  2025cites this paper
• High-performance Open-source AI for Breast Cancer Detection and Localization in MRI.

  2025cites this paper
• Ramucirumab and paclitaxel in second or greater lines of therapy in patients with HER2-positive gastroesophageal cancer: a single center study

  2025cites this paper
• Healthcare costs and health outcomes analysis of Neoadjuvant Trastuzumab therapy for HER2 positive breast cancer.

  2025cites this paper
• Design, novel one-pot green synthesis, and biological evaluation of pyrazolopyridine-congeners selectively targeting HER2+ breast cancer.

  2025cites this paper
• Cardiotoxicity in Breast Cancer Therapy: Risks, Mechanisms, and Prevention Strategies

  2025cites this paper
• A study to compare the efficacy of neoadjuvant chemotherapy in locally advanced human epidermal growth factor receptor 2 overexpressing breast cancer

  2025cites this paper
• What Powers Trastuzumab's Cardiotoxicity? Decoding Mitochondrial-Related Gene Expression Through Integrative Review and Meta-Analysis in Cardiomyocytes

  2024influential citation
• Bước đầu đánh giá hiệu quả điều trị bổ trợ của ung thư vú Her-2 dương tính giai đoạn chưa di căn xa

  2024cites this paper
• Quality-adjusted life years for HER2-positive, early-stage breast cancer using trastuzumab-containing regimens in the context of cost-effectiveness studies: a systematic review

  2024cites this paper
• Validation of the AJCC 8th Edition Breast Cancer Prognostic Staging System in Legacy Alliance Trials (AFT-01)

  2024cites this paper
• Cost-effectiveness of one-year adjuvant trastuzumab therapy in treatment for early-stage breast cancer patients with HER2+ in Vietnam

  2024cites this paper
• Endocrine therapy plus HER2-targeted therapy, another favorable option for HR+/HER2+ advanced breast cancer patients

  2024cites this paper
• Enhanced bacterial cancer therapy delivering therapeutic RNA interference of c-Myc

  2024cites this paper
• The multidisciplinary management of HER2-positive breast cancer brain metastases: from new biological insights to future therapeutic options

  2024cites this paper
• Left atrial strain is reduced following trastuzumab in breast cancer patients

  2024cites this paper
• Uptake of biosimilars in China: a retrospective analysis of the case of trastuzumab from 2018 to 2023

  2024cites this paper
• Evaluating high-sensitivity cardiac troponin I for early detection of treatment-related cardiotoxicity in HER2-positive breast cancer patients

  2024cites this paper
• The Population-level Effect of Adjuvant Therapies on Breast Cancer Recurrence: Application of the Trend-in-Trend Design

  2024cites this paper
• Real-World Study of Adjuvant Biosimilar Trastuzumab-dkst for HER2-Positive Breast Cancer Treatment in a Brazilian Population

  2024influential citation
• Breast cancer patient-derived organoids for the investigation of patient-specific tumour evolution

  2024influential citation
• Context-Specific Estimation of Future Unrelated Medical Costs and Their Impact on Cost-Effectiveness Analyses

  2023cites this paper
• Intratumoral heterogeneity, treatment response, and survival outcome of ER‐positive HER2‐positive breast cancer

  2023cites this paper
• Trastuzumab potentiates doxorubicin-induced cardiotoxicity via activating the NLRP3 inflammasome in vivo and in vitro.

  2023cites this paper
• Clinical sequencing identifies potential actionable alterations in a high rate of urachal and primary bladder adenocarcinomas

  2023cites this paper
• Clinical management of drug-induced cardiotoxicity in patients with HER-2+ breast cancer: current recommendations and future outlook

  2023cites this paper
• Molecular Testing for Diagnostics, Prognostication, and Treatment Stratification in Cancers.

  2023cites this paper
• Recommendations for the diagnosis and treatment of patients with early breast cancer: update 2023

  2023cites this paper
• Weakly supervised bilayer convolutional network in segmentation of HER2 related cells to guide HER2 targeted therapies

  2023cites this paper
• 5G-Based Telerobotic Ultrasound System Improves Access to Breast Examination in Rural and Remote Areas: A Prospective and Two-Scenario Study

  2023cites this paper
• HER2 status as a potential predictive biomarker for ovarian clear cell carcinoma

  2023cites this paper
• Prognostic significance of TP53 and PIK3CA mutations analyzed by next-generation sequencing in breast cancer

  2023cites this paper
• Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer (PICTURE): a single-arm, multicenter phase 2 trial

  2023cites this paper
• Status and prognostic value of immunological biomarkers of breast cancer

  2023cites this paper
• Clinical significance of CD166 and HER-2 in different types of gastric cancer

  2023cites this paper
• Cardiovascular sequelae of trastuzumab and anthracycline in long-term survivors of breast cancer

  2023cites this paper
• Safety survey on infusion reaction and cardiac dysfunction when switching from reference trastuzumab (HERCEPTIN®) to biosimilar trastuzumab (Trastuzumab‑NK) in the treatment of HER2‑positive breast cancer

  2023cites this paper
• Cost-effectiveness analysis of trastuzumab monotherapy versus adjuvant chemotherapy plus trastuzumab in elderly patients with HER2-positive early breast cancer.

  2022cites this paper
• Acute skin radiation toxicity seen with concurrent T-DM1: A single institutional report of 35 patients

  2022cites this paper
• ABSDELL Model: Development and Internal Validation of a Risk Prediction Model of LVEF Decline in Breast Cancer Patients Treated With Trastuzumab.

  2022cites this paper
• The association of trastuzumab with atrial fibrillation and heart failure in breast cancer patients in routine clinical practice: a population-based propensity score matching and competing risk model analysis

  2022cites this paper
• PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer

  2022cites this paper
• Tailoring antiHer2 treatment strategies in breast cancer and beyond.

  2022cites this paper
• Targeted therapy for breast cancer: An overview of drug classes and outcomes.

  2022cites this paper
• Breast Cancer—Epidemiology, Classification, Pathogenesis and Treatment (Review of Literature)

  2022cites this paper
• Defucosylated Mouse-Dog Chimeric Anti-Human Epidermal Growth Factor Receptor 2 Monoclonal Antibody (H77Bf) Exerts Antitumor Activities in Mouse Xenograft Models of Canine Osteosarcoma

  2022cites this paper
• Loss of human epidermal receptor-2 in human epidermal receptor-2+ breast cancer after neoadjuvant treatment: A case report

  2022cites this paper
• HER-2-Targeted Nanoparticles for Breast Cancer Diagnosis and Treatment

  2022cites this paper
• 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).

  2022cites this paper
• Functional mechanism and clinical implications of miR-141 in human cancers.

  2022cites this paper
• Management of breast cancer in older patients.

  2022cites this paper
• Trastuzumab

  2022cites this paper
• Dormancy in Breast Cancer, the Role of Autophagy, lncRNAs, miRNAs and Exosomes

  2022cites this paper
• HER2 (ERBB2) alterations in colorectal cancers

  2022cites this paper
• 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).

  2022cites this paper
• Adjuvant trastuzumab without chemotherapy for treating early HER2-positive breast cancer in older patients: A propensity score-adjusted analysis of a prospective cohort study

  2022cites this paper
• Systematic review of the evidence sources applied to cost-effectiveness analyses for older women with primary breast cancer

  2022cites this paper
• Not all small HER2 positive breast cancers have the same clinical outcome in the North-East of Scotland.

  2022cites this paper
• Cardiotoxicity is mitigated after a supervised exercise program in HER2-positive breast cancer undergoing adjuvant trastuzumab

  2022cites this paper
• Cost-Effectiveness of Trastuzumab With or Without Chemotherapy as Adjuvant Therapy in HER2-Positive Elderly Breast Cancer Patients: A Randomized, Open-Label Clinical Trial, the RESPECT Trial

  2022cites this paper
• Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients

  2022cites this paper
• Calculators for the assessment of need for drugs in oncology: justification of necessity and comparative characteristics

  2021cites this paper
• The role of cardiac biomarkers in early detection of cardiotoxicity in breast cancer treated with trastuzumab in the adjuvant setting: a systematic review

  2021cites this paper
• Human epidermal growth factor receptor 2 is overexpressed in canine prostate carcinoma

  2021cites this paper
• A Novel Small Molecular Antibody, HER2-Nanobody, Inhibits Tumor Proliferation in HER2-Positive Breast Cancer Cells In Vitro and In Vivo

  2021cites this paper
• Health-Related Quality of Life With Trastuzumab Monotherapy Versus Trastuzumab Plus Standard Chemotherapy as Adjuvant Therapy in Older Patients With HER2-Positive Breast Cancer

  2021cites this paper
• Building Bridges Between Drug Development and Cancer Science: A Tribute to José Baselga's Legacy.

  2021cites this paper
• Enhanced Angiogenesis in Salivary Duct Carcinoma Ex-Pleomorphic Adenoma

  2021cites this paper
• Clinical predictors of cardiac toxicity in HER2-positive early breast cancer patients treated with adjuvant s.c. versus i.v. trastuzumab

  2021cites this paper
• PTEN is a predictive biomarker of trastuzumab resistance and prognostic factor in HER2-overexpressing gastroesophageal adenocarcinoma

  2021cites this paper
• ErbB2 copy number gain is associated with adverse outcome in canine mammary carcinoma

  2021cites this paper
• Heart failure prevention and monitoring strategies in HER2-positive breast cancer: a narrative review

  2021cites this paper
• Heregulin-induced cell migration is prevented by trastuzumab and trastuzumab-emtansine in HER2+ breast cancer

  2021cites this paper
• Analytical validation of human epidermal growth factor receptor 2 immunohistochemistry by the use of the A0485 antibody versus the 4B5 antibody and breast versus gastric scoring guidelines in ovarian clear cell carcinoma

  2021cites this paper
• Controversies of radiotherapy in human epidermal growth factor receptor (HER)-2 positive breast cancer patients.

  2021cites this paper
• Racial disparities in mortality outcomes among women diagnosed with breast cancer in Maryland: Impact of cardiovascular disease and clinical characteristics

  2021cites this paper
• Ключевые исследования, изменившие историю и принципы лечения раннего HER2+ рака молочной железы: фокус на индивидуализацию терапии

  2021cites this paper
• Anticancer Impact of Nitric Oxide (NO) and NO Combination with SMYD-3 Inhibitor on Breast Carcinomas

  2021cites this paper
• Affibody-Mediated PNA-Based Pretargeted Cotreatment Improves Survival of Trastuzumab-Treated Mice Bearing HER2-Expressing Xenografts

  2021cites this paper
• Targeted Agents for HER2-Positive Breast Cancer: Optimal Use in Older Patients

  2021cites this paper
• HER-2 as a Prognostic and Predictive Biomarker in Cancer

  2021cites this paper
• Adjuvant Trastuzumab Without Chemotherapy For Treating Early HER2-Positive Breast Cancer In Older Patients: A Cohort Study Accompanying With The RESPECT Trial

  2021cites this paper
• Pharmacological Basis of Breast Cancer Resistance to Therapies - An Overview.

  2021cites this paper
• Impact of Trastuzumab on Ipsilateral Breast Tumor Recurrence for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer after Breast-Conserving Surgery

  2021cites this paper
• Influence of Ile655Val polymorphism on trastuzumab-induced cardiotoxicity in early-stage HER2 positive breast cancer

  2021cites this paper
• Investigating molecular targets of the DNA damage response in triple negative breast cancer

  2021cites this paper
• Adjuvant therapy in older patients with breast cancer

  2021cites this paper
• Clinical Relevance and Prognostic Value of the Neuronal Protein Neuroligin 2 in Breast Cancer

  2020cites this paper
• The role of antibody expression and their association with bladder cancer recurrence: a single-centre prospective clinical-pilot study in 35 patients

  2020cites this paper
• Screening of Clinical Factors Related to Prognosis of Breast Cancer Based on the Cox Proportional Risk Model.

  2020cites this paper
• Do all patients with HER2 positive breast cancer require one year of adjuvant trastuzumab? A systematic review and meta-analysis

  2020cites this paper
• HER2 Status in High-Risk Endometrial Cancers (PORTEC-3): Relationship with Histotype, Molecular Classification, and Clinical Outcomes

  2020cites this paper
• Clinical impact of interruption in adjuvant Trastuzumab therapy in patients with operable HER-2 positive breast cancer

  2020cites this paper
• Preparation and characterization of antibody-drug conjugates acting on HER2-positive cancer cells

  2020cites this paper
• Adjuvant Trastuzumab Emtansine (T-DM1) and Concurrent Radiotherapy for Residual Invasive HER2-positive Breast Cancer

  2020cites this paper
• Aptamer-Protamine-siRNA nanoparticles in targeted therapy of ErbB3 positive breast cancer cells.

  2020cites this paper